HCPCS J0603: Sevelamer Hydrochloride Oral 20 mg for ESRD on Dialysis - OpenPayer

Summary & Overview

HCPCS J0603: Sevelamer Hydrochloride Oral 20 mg for ESRD on Dialysis

HCPCS Level II code J0603 designates sevelamer hydrochloride (Renagel or therapeutically equivalent), oral, 20 mg, used to manage hyperphosphatemia in patients with end-stage renal disease on dialysis. This pharmaceutical HCPCS code identifies a specific oral formulation dispensed for dialysis-dependent patients and has implications for pharmacy benefit management, dialysis facility medication administration, and Medicare Part B/Part D and commercial payer coverage policies. Nationally, accurate coding of oral phosphate binders affects medication access, coverage determinations, and payment reconciliation for dialysis programs.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn about the clinical context for using sevelamer in dialysis patients, typical sites of service where the medication is dispensed or administered, and the types of benchmarks and policy items commonly associated with HCPCS pharmaceutical codes (coverage scope, site-of-service considerations, and payer coverage patterns). The publication also outlines areas where billing clarity is important for aligning pharmacy claims with dialysis services and for payer adjudication. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ0603HCPCS Level IIsevelamerpharmacyend-stage renal diseasedialysisphosphate bindermedication coding

Billing Code Overview

HCPCS Level II code J0603 represents sevelamer hydrochloride (Renagel or therapeutically equivalent), oral, 20 mg formulation intended for patients with end-stage renal disease (ESRD) on dialysis. This code covers the oral phosphate binder product used to manage hyperphosphatemia in dialysis-dependent patients.

Service type: Oral pharmaceutical therapy for ESRD on dialysis

Typical site of service: Outpatient pharmacy or hospital outpatient setting for dialysis patients

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is a 58-year-old individual with end-stage renal disease (ESRD) on maintenance hemodialysis who presents for routine nephrology follow-up and medication management of hyperphosphatemia. The patient has persistently elevated serum phosphorus despite dietary measures and requires initiation or continuation of an oral phosphate binder. In clinic, the nephrologist or dialysis clinic nurse documents current labs, reviews dialysis adequacy, confirms oral intake and concomitant medications, and prescribes sevelamer hydrochloride. The medication is dispensed through the outpatient pharmacy or dialysis facility, with dosing adjusted based on serum phosphorus levels and tolerability. Routine follow-up includes monitoring serum phosphorus, calcium, and parathyroid hormone (PTH) and assessing gastrointestinal tolerability and adherence. This service is provided in outpatient nephrology clinics, chronic dialysis centers, and outpatient pharmacies; medication administration is oral and self-administered by the patient at home, with dispensing and medication management services provided during clinic or dialysis visits.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard service	Use when no special circumstances apply to the medication dispensing or prescription claim
`22`

HCPCS Level II J0401: Aripiprazole (Abilify Maintena) Injection, 1 mg

HCPCS-J2503-PEGAPTANIB-SODIUM-INJECTION-0-3-MG

HCPCS J2503: Injection, pegaptanib sodium, 0.3 mg

HCPCS-J0567-CERLIPONASE-ALFA-INJECTION-1MG

HCPCS J0567: Injection, Cerliponase Alfa, 1 mg

HCPCS-J2468-PALONOSETRON-INJECTION-25-MCG

HCPCS Level II J2468: Palonosetron Injection, 25 micrograms

HCPCS-J3105-TERBUTALINE-INJECTION-UP-TO-1MG

HCPCS Level II J3105: Terbutaline Sulfate Injection, Up to 1 mg

HCPCS-J7318-DUROLANE-INTRA-ARTICULAR-INJECTION-1MG

HCPCS J7318: Durolane, Intra-articular Hyaluronan Injection, 1 mg

HCPCS-J1741-IBUPROFEN-INJECTION-100MG

HCPCS J1741: Injection, Ibuprofen 100 mg

HCPCS-J7645-IPRATROPIUM-INHALATION-COMPOUNDED-DME-UNIT-DOSE

HCPCS J7645: Ipratropium Bromide Inhalation Solution, Compounded, DME Unit-Dose

HCPCS-J7657-ISOPROTERENOL-INHALATION-COMPOUNDED-DME

HCPCS J7657: Isoproterenol HCl Inhalation Solution, Compounded

HCPCS-J2185-MEROPENEM-100MG-INJECTION

HCPCS Level II J2185: Injection, meropenem, 100 mg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`2080P0800X`	Nephrology	Primary specialty managing ESRD and phosphate binder therapy
`368000000X`	Dialysis Facility	Location-based taxonomy for chronic hemodialysis care and medication management at dialysis centers
`364SF0200X`	Pharmacy	Outpatient pharmacy dispensing and medication counseling services
`208D00000X`	Internal Medicine	Common primary care specialty co-managing chronic kidney disease and medication reconciliation
`363L00000X`	Nurse Practitioner	Frequently provides medication management and patient education in outpatient and dialysis settings

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E83.49`	Other disturbances of phosphorus metabolism	Reflects disorders of phosphorus homeostasis; can indicate hyperphosphatemia warranting phosphate binder therapy
`N18.6`	End stage renal disease	Primary indication for dialysis-dependent patients who commonly require sevelamer to control serum phosphorus
`N18.5`	Chronic kidney disease, stage 5	Advanced CKD often requires phosphate binders to manage mineral bone disease prior to or during dialysis initiation
`E83.3`	Disorders of phosphorus metabolism	Broad category used when documenting phosphorus metabolic disturbances leading to treatment
`M80.00XA`	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter	Included as an associated diagnosis when mineral bone disorder contributes to fracture risk; phosphate binders are part of mineral metabolism management
`E83.39`	Other disorders of phosphorus metabolism	Additional code option for specific phosphorus metabolism disorders associated with need for phosphate binders

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M visit code used when the nephrologist or advanced practice provider assesses ESRD patient and manages phosphate binder therapy
`99347`	Prolonged physician service in the outpatient setting requiring direct patient contact, first hour (used with E/M)	Used when additional time is spent on complex medication education or reconciliation related to sevelamer therapy
`99605`	Medication therapy management service(s) provided by a pharmacist, initial 15 minutes, face-to-face with patient, new patient	Used when a pharmacist provides medication therapy management at initiation of sevelamer therapy (note payer-specific coverage)
`90791`	Psychiatric diagnostic evaluation (no medical services)	Not directly related; included only when behavioral health intersects with medication adherence issues (rare)
`99072`	Additional supplies, materials, and clinical staff time over and above those usually included in a procedure due to COVID-19 pandemic, per day	Occasionally appended to account for extra infection control measures during in-clinic dispensing (payer policies vary)

OpenPayer